The Impact of METTL14 on the Proliferation, Invasion, 
and Migration of Triple-Negative Breast Cancer Cells

Zhiwei Qin*; Erni Zhou*; Wenrang Songyuan

doi:10.70711/pmr.v2i4.6107

The Impact of METTL14 on the Proliferation, Invasion, and Migration of Triple-Negative Breast Cancer Cells

Zhiwei Qin*, Erni Zhou*, Wenrang Songyuan

Abstract

Objective: To explore the impacts of METTL14 upon the proliferation, invasion, and migration of triple-negative breast cancer
(TNBC) cells. Method: Stable METTL14-overexpressing and METTL14-knockdown TNBC cell lines were constructed. The proliferation,
invasion, and migration abilities of the cells were assessed using CCK-8 assays and Transwell assays. Result: CCK-8 assay results demonstrated that METTL14 significantly promoted TNBC cell proliferation (P < 0.05). Transwell assays revealed that METTL14 enhanced the
invasion and migration abilities of TNBC cells (P < 0.05). Conclusion: METTL14 potentially augments the proliferation, invasion, and
migration of TNBC cells, presumably by means of mechanisms correlated with the PI3K/Akt signaling cascade and the EMT (EpithelialMesenchymal Transition) process.

Keywords

Triple-negative breast cancer; METTL14; Breast cancer; Proliferation; Invasion and migration

Full Text:

PDF

Included Database

References

[1] Yin L, Duan JJ, Bian XW, etal. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020,

22(1):61

[2] Qi YN, Liu Z, Hong LL, etal. Methyltransferase-like proteins in cancer biology and potential therapeutic targeting. J Hematol Oncol.

2023, 16(1):89

[3] Guan Q, Lin H, Miao L, etal. Functions, mechanisms, and therapeutic implications of METTL14 in human cancer. J Hematol Oncol.

2022, 15(1):13

[4] Wang Z, Jiang Q, Dong C. Metabolic reprogramming in triple-negative breast cancer. Cancer Biol Med. 2020, 17(1):44-59

[5] Miglietta F, Dieci MV. How can we refine the prognostic stratification of triple-negative breast cancer? Expert Rev Anticancer Ther.

2023, 23(10):1045-1047

[6] Shaikh SS, Emens LA. Current and emerging biologic therapies for triple negative breast cancer. Expert Opin Biol Ther. 2022,

22(5):591-602

[7] Popovic LS, Matovina-Brko G, Popovic M, etal. Targeting triple-negative breast cancer: A clinical perspective. Oncol Res. 2023,

31(3):221-238

[8] An S, Huang W, Huang X, etal. Integrative network analysis identifies cell-specific trans regulators of m6A. Nucleic Acids Res. 2020,

48(4):1715-1729

[9] Narod SA, Dent R. Triple-negative breast cancers. Expert Rev Anticancer Ther. 2023, 23(10):1041-1043

[10] Nath A, Mitra S, Mistry T, Pal R, Nasare VD. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.

Med Oncol. 2021, 39(1):14

DOI: http://dx.doi.org/10.70711/pmr.v2i4.6107

Refbacks

There are currently no refbacks.